Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.

Abstract: The present invention provides phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds, to pharmaceutical compositions comprising the compounds, to methods of using the compounds to treat physiological disorders such as cancer.

Abstract: This invention provides certain piperidine compounds as AT2R antagonists, e.g., compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and X are as defined herein, pharmaceutical compositions thereof, and methods of using the same to treat pain associated with AT2R activity.

Abstract: The present invention provides phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds, such as compounds of formula I: pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat physiological disorders such as pancreatic cancer.

Abstract: The present invention provides 5-[5]-[2-cycloalkyl]-6-pyridazin-3-yl]-1H-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer.

Abstract: The present invention provides 5-[5]-[2-cycloalkyl]-6-pyridazin-3-yl]-1H-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer.

Abstract: The present disclosure relates to processes for recovering rare earth elements from an aluminum-bearing material. The processes can comprise leaching the aluminum-bearing material with an acid so as to obtain a leachate comprising at least one aluminum ion, at least one iron ion, at least one rare earth element, and a solid, and separating the leachate from the solid. The processes can also comprise substantially selectively removing at least one of the at least one aluminum ion and the at least one iron ion from the leachate and optionally obtaining a precipitate. The processes can also comprise substantially selectively removing the at least one rare earth element from the leachate and/or the precipitate.

Abstract: The present disclosure relates to processes for recovering rare earth elements from various materials. The processes can comprise leaching the at least one material with at least one acid so as to obtain a leachate comprising at least one metal ion and at least one rare earth element, and a solid, and separating the leachate from the solid. The processes can also comprise substantially selectively removing at least one of the at least one metal ion from the leachate and optionally obtaining a precipitate. The processes can also comprise substantially selectively removing the at least one rare earth element from the leachate and/or the precipitate.

Abstract: The present disclosure relates to processes for recovering rare earth elements from an aluminum-bearing material. The processes can comprise leaching the aluminum-bearing material with an acid so as to obtain a leachate comprising at least one aluminum ion, at least one iron ion, at least one rare earth element, and a solid, and separating the leachate from the solid. The processes can also comprise substantially selectively removing at least one of the at least one aluminum ion and the at least one iron ion from the leachate and optionally obtaining a precipitate. The processes can also comprise substantially selectively removing the at least one rare earth element from the leachate and/or the precipitate.

Abstract: The present disclosure relates to processes for recovering rare earth elements from an aluminum-bearing material. The processes can comprise leaching the aluminum-bearing material with an acid so as to obtain a leachate comprising at least one aluminum ion, at least one iron ion, at least one rare earth element, and a solid, and separating the leachate from the solid. The processes can also comprise substantially selectively removing at least one of the at least one aluminum ion and the at least one iron ion from the leachate and optionally obtaining a precipitate. The processes can also comprise substantially selectively removing the at least one rare earth element from the leachate and/or the precipitate.

Abstract: The present disclosure relates to processes for recovering rare earth elements from various materials. The processes can comprise leaching the at least one material with at least one acid so as to obtain a leachate comprising at least one metal ion and at least one rare earth element, and a solid, and separating the leachate from the solid. The processes can also comprise substantially selectively removing at least one of the at least one metal ion from the leachate and optionally obtaining a precipitate. The processes can also comprise substantially selectively removing the at least one rare earth element from the leachate and/or the precipitate.

Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.

Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.

Abstract: The reaction occurs in a medium buffered with phosphate in an aqueous medium, at neutral pH and at room temperature. Hence, the reaction medium consists of: tyrosol, as precursor; (commercial) mushroom tyrosinase to catalyze the process and vitamin C in excess. Reaction starts after initial shaking. The reaction stops when the concentration of the initial tyrosol is exhausted. In order for the reaction to continue, it will suffice to add more tyrosol (always ensuring that the vitamin C/tyrosol ratio is more than 1). Once the desired concentration of hydroxytyrosol is obtained, it is filtered. The enzyme with molecular weight over twice the size of the pore is retained in the filter and can be used once again. This first extract, which is very enriched in antioxidant hydroxytyrosol with a high antioxidant capacity (in the present case, in combination with vitamin C), can already be used as a food additive.